Study
| Randomized, open-label, international, multicenter phase III study |
| Advanced GIST who progressed on or were intolerant to first-line treatment with imatinib |
| Ripretinib 150 mg (n = 226) or sunitinib 50 mg (4/2, n = 227) |
Efficacy
| mPFS: 8.3 m vs 7 months (HR, 0.88; P = .36) for KIT exon 11 ITT |
| ORR: 23.9% v 14.6%, P = .03 |
Safety
| Grade ≥3 AEs: 26.5% vs 55.2% |
| Drug related death: 0 vs 0.5% |
| Any grade TRAE: alopecia (64.1%), fatigue (37.7%), myalgia (36.3%) for ripretinib and Palmar-plantar erythrodysesthesia syndrome (51.1%), diarrhea (48.0%), hypertension (47.1%) for sunitinib |
J Clin Oncol. 2022 Aug 10;JCO2200294.
http://doi.org/10.1200/jco.22.00294
Reviewed by Hasan Cagri Yildirim, MD on Sep 20, 2022
